--- title: "$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR)" type: "News" locale: "en" url: "https://longbridge.com/en/news/300474696.md" description: "Monteverde & Associates PC, a securities class action firm, has announced an investigation into Lifecore Biomedical, Inc. (NASDAQ: LFCR) regarding its proposed sale to affiliates of Webster Equity Partners. Under the deal terms, shareholders are set to receive $6.28 in cash per share plus one non-transferable contingent value right per share, which may yield additional payments based on revenue and EBITDA milestones through 2030." datetime: "2026-09-29T18:52:26.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/300474696.md) - [en](https://longbridge.com/en/news/300474696.md) - [zh-HK](https://longbridge.com/zh-HK/news/300474696.md) generator: "portal-rs" --- # $HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lifecore Biomedical, Inc. (NASDAQ: LFCR) , /PRNewswire/ -- **Class Action Attorney Juan Monteverde with Monteverde & Associates PC** (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a **Top 50 Firm** in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the **Empire State Building** in New York City and is investigating **Lifecore Biomedical, Inc. (NASDAQ: LFCR)** related to its sale to affiliates of Webster Equity Partners. Under the terms of the proposed transaction, Lifecore shareholders are expected to receive $6.28 in cash per share, plus one non-transferable contingent value right per share, entitling holders to potential additional cash payments based on the Company's achievement of specified revenue and EBITDA milestones through 2030. **Is it a fair deal?** **Click here for more info** https://monteverdelaw.com/case/lifecore-biomedical-inc/. **It is free and there is no cost or obligation to you.** **NOT ALL LAW FIRMS ARE EQUAL.** Before you hire a law firm, you should talk to a lawyer and ask: 1\. Do you file class actions and go to Court? 2\. When was the last time you recovered money for shareholders? 3\. What cases did you recover money in and how much? **About Monteverde & Associates PC** Our firm litigates and has recovered money for shareholders...and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. **No one is above the law.** If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at \[email protected\] or by telephone at (212) 971-1341. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC **The Empire State Building** 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America \[email protected\] Tel: (212) 971-1341 Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter. SOURCE Monteverde & Associates PC ### Related Stocks - [LFCR.US](https://longbridge.com/en/quote/LFCR.US.md) ## Related News & Research - [Lifecore Biomedical, Inc. (NASDAQ:LFCR) Receives Average Rating of "Reduce" from Analysts](https://longbridge.com/en/news/300570979.md) - [LFCR SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER BUYOUT FAIRLY VALUES LIFECORE BIOMEDICAL, INC.](https://longbridge.com/en/news/300330454.md) - [Carderock Capital Management Inc. Sells 8,453 Shares of The Home Depot, Inc. $HD](https://longbridge.com/en/news/302957293.md) - [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md) - [MRNA: Intismeran plus pembrolizumab improved RFS and DMFS in resected melanoma](https://longbridge.com/en/news/302972013.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**